General MedicationsORALStandard
LAMIVUDINE
LAMIVUDINE
Standard Dose
300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview LAMIVUDINE is listed in Drugs@FDA under application 206974 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient LAMIVUDINE Form and strength TABLET;ORAL - 300MG Sponsor SOMERSET THERAPS LLC Submission history Latest submission status date: 2019-10-07 00:00:00.
Structured Monograph
Clinical summary
Approval overview LAMIVUDINE is listed in Drugs@FDA under application 206974 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LAMIVUDINE Form and strength TABLET;ORAL - 300MG Sponsor SOMERSET THERAPS LLC Submission history Latest submission status date: 2019-10-07 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.